临床试验/NCT00097279

NCT00097279已完成3 期

A Multicenter, Open-Label, Randomised Trial to Compare the Efficacy and Safety of NovoLog Mix 70/30 BID in Combination With Metformin and Pioglitazone to Metformin and Pioglitazone Alone in Insulin Naïve Subjects With Type 2 Diabetes

Novo Nordisk A/S74 个研究点分布在 1 个国家目标入组 230 人开始时间: 2004年8月最近更新: 2017年1月11日

适应症

试验速览

阶段: 3 期
状态: 已完成
发起方: Novo Nordisk A/S
入组人数: 230
试验地点: 74
主要终点: HbA1c

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This trial is conducted in the United States of America (USA). The purpose of this study is to test whether biphasic insulin aspart 70/30 is a safe and at least as effective alternative in combination with two oral anti-diabetics compared to the two oral anti-diabetics alone for the control of blood glucose.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Subjects with type 2 diabetes mellitus

排除标准

未提供

结局指标

主要结局

HbA1c

时间窗: After 24 weeks

次要结局

Safety variables
Other glycemic variables
8-point plasma glucose profiles

研究者

发起方

Novo Nordisk A/S

申办方类型

Industry

责任方

Sponsor

研究点 (74)

Loading locations...

相似试验

已完成

4 期

NovoLog Observation Trial in Subjects With Type 1 and Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1

NCT00095446Novo Nordisk A/S513

已完成

4 期

Novofine Autocover Safety Needle Versus BD Safety GlideHealthcare ProfessionalsDelivery SystemsDiabetes

NCT00121355Novo Nordisk A/S83

已完成

3 期

Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in DiabeticsDelivery SystemsDiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2

NCT00773279Novo Nordisk A/S242

已完成

4 期

Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major SurgeryCongenital Bleeding DisorderHaemophilia A With InhibitorsHaemophilia B With Inhibitors

NCT01561391Novo Nordisk A/S36

终止

2 期

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell TransplantationAcquired Bleeding DisorderBleeding During/Following Surgery

NCT01564563Novo Nordisk A/S11